Martin Kropff

7.8k total citations · 1 hit paper
69 papers, 3.1k citations indexed

About

Martin Kropff is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Martin Kropff has authored 69 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Hematology, 33 papers in Molecular Biology and 33 papers in Oncology. Recurrent topics in Martin Kropff's work include Multiple Myeloma Research and Treatments (59 papers), Cancer Treatment and Pharmacology (21 papers) and Protein Degradation and Inhibitors (21 papers). Martin Kropff is often cited by papers focused on Multiple Myeloma Research and Treatments (59 papers), Cancer Treatment and Pharmacology (21 papers) and Protein Degradation and Inhibitors (21 papers). Martin Kropff collaborates with scholars based in Germany, Italy and Greece. Martin Kropff's co-authors include Wolfgang E. Berdel, Joachim Kienast, Meletios Α. Dimopoulos, Rolf M. Mesters, Teresa Padró, Helgi van de Velde, Berno Dankbar, Regine Leo, Antonio Palumbo and Jesús F. San Miguel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Martin Kropff

69 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Kropff Germany	26	2.5k	2.1k	1.7k	368	183	69	3.1k
Lotfi Benboubker France	26	3.0k 1.2×	2.7k 1.3×	2.0k 1.2×	571 1.6×	191 1.0×	101	3.7k
William Deraedt United States	15	2.2k 0.9×	1.7k 0.8×	1.5k 0.9×	410 1.1×	199 1.1×	56	2.7k
Dixie Esseltine United States	22	1.9k 0.7×	1.8k 0.9×	1.6k 1.0×	539 1.5×	506 2.8×	44	3.1k
Raymond Powles United Kingdom	10	2.2k 0.9×	1.4k 0.7×	1.1k 0.7×	332 0.9×	152 0.8×	14	2.5k
Annamaria Brioli Italy	20	1.8k 0.7×	1.3k 0.6×	954 0.6×	255 0.7×	167 0.9×	72	2.2k
Robert M. Rifkin United States	26	1.6k 0.6×	1.4k 0.7×	1.2k 0.7×	248 0.7×	142 0.8×	143	2.5k
Thomas Moehler Germany	25	1.4k 0.5×	1.1k 0.5×	739 0.4×	281 0.8×	158 0.9×	69	2.1k
María Teresa Cibeira Spain	23	1.3k 0.5×	1.3k 0.6×	709 0.4×	398 1.1×	105 0.6×	91	2.0k
Dixie‐Lee Esseltine United States	11	1.1k 0.4×	1.2k 0.6×	817 0.5×	285 0.8×	190 1.0×	12	1.8k
Paola Omedè Italy	28	1.7k 0.7×	1.3k 0.6×	1.0k 0.6×	508 1.4×	281 1.5×	112	2.7k

Countries citing papers authored by Martin Kropff

Since Specialization

Citations

This map shows the geographic impact of Martin Kropff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kropff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kropff more than expected).

Fields of papers citing papers by Martin Kropff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kropff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kropff. The network helps show where Martin Kropff may publish in the future.

Co-authorship network of co-authors of Martin Kropff

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kropff. A scholar is included among the top collaborators of Martin Kropff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kropff. Martin Kropff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kropff, Martin, Martin Vogel, Guido Bisping, et al.. (2017). Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Annals of Hematology. 96(11). 1857–1866. 14 indexed citations

Thoennissen, Gabriela B., Dennis Görlich, Ulrike Bacher, et al.. (2017). Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematologica. 137(3). 163–172. 8 indexed citations

Gerth, Hans Ulrich, Michele Pohlen, Dennis Görlich, et al.. (2016). Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS ONE. 11(5). e0154993–e0154993. 18 indexed citations

Dimopoulos, Meletios Α., Michel Delforge, Roman Hájek, et al.. (2012). Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 98(5). 784–788. 48 indexed citations

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440. 661 indexed citations breakdown →

Palumbo, Antonio, Meletios Α. Dimopoulos, Michel Delforge, et al.. (2010). A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM). 95. 234–235. 12 indexed citations

Dimopoulos, Meletios Α., María-Victoria Mateos, Paul G. Richardson, et al.. (2010). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal Of Haematology. 86(1). 23–31. 100 indexed citations

Delforge, Michel, Joan Bladé, Meletios Α. Dimopoulos, et al.. (2010). Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet Oncology. 11(11). 1086–1095. 157 indexed citations

Palumbo, Antonio, Faith E. Davies, Martin Kropff, et al.. (2010). Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of Hematology. 89(8). 803–811. 24 indexed citations

10.

Heeg, Bart, Michel van Agthoven, Johan Liwing, et al.. (2010). Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. Blood. 116(21). 3046–3046. 4 indexed citations

11.

Moehler, Thomas, Reinhard Feneberg, Anthony D. Ho, et al.. (2010). Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anti-Cancer Drugs. 21(7). 708–715. 6 indexed citations

12.

Mateos, María‐Victoria, Paul G. Richardson, Rudolf Schlag, et al.. (2010). Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. Journal of Clinical Oncology. 28(13). 2259–2266. 312 indexed citations

13.

Donk, Niels W.C.J. van de, Henk M. Lokhorst, Meletios Α. Dimopoulos, et al.. (2010). Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews. 37(4). 266–283. 51 indexed citations

14.

Kreuter, Michael, Martin Kropff, Klaus Junker, et al.. (2009). Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. European Respiratory Journal. 33(6). 1383–1388. 12 indexed citations

15.

Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations

16.

Kropff, Martin, et al.. (2006). Proteasome inhibition in multiple myeloma. European Journal of Cancer. 42(11). 1623–1639. 23 indexed citations

17.

Fenk, Roland, Philipp Schneider, Martin Kropff, et al.. (2005). High‐dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment‐related mortality in patients with multiple myeloma: results of a randomised study. British Journal of Haematology. 130(4). 588–594. 37 indexed citations

18.

Bisping, Guido, Martin Kropff, Sergey Bessonov, et al.. (2005). Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood. 107(5). 2079–2089. 28 indexed citations

19.

Tchinda, Joëlle, Martin Kropff, Wolfgang E. Berdel, et al.. (2004). Frequent Gains of the Short Arm of Chromosome 9 in Multiple Myeloma With Normal G-Banded Karyotype Detected by Comparative Genomic Hybridization. American Journal of Clinical Pathology. 122(6). 875–882. 3 indexed citations

20.

Kropff, Martin, Nicola Lang, Guido Bisping, et al.. (2003). Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology. 122(4). 607–616. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact